ISIga

ISIga is a biological treatment for irritable bowel syndrome (IBS) and other gastrointestinal disorders. The treatment consists of a proprietary blend of four strains of Lactobacillus and Bifidobacterium bacteria, which are live cultures that are added to a patient's diet.

Research on ISIga has shown that it can help alleviate symptoms of IBS, including abdominal pain, bloating, and changes in bowel movements. The treatment has been found to be effective in reducing the frequency and severity of these symptoms in patients with mild to moderate IBS.

ISIga works by introducing healthy bacteria into the gut, where they can help to crowd out pathogenic microorganisms and improve the balance of the gut microbiome. This can lead to improved digestion, reduced inflammation, and enhanced immune function.

ISIga has been studied in several clinical trials, including a phase 2 trial that demonstrated its efficacy in treating mild to moderate IBS. The treatment has been found to be safe and well-tolerated, with no significant side effects reported.

ISIga is classified as a medical food, which means that it is a nutrient-fortified product that is intended to be used as part of a medical treatment plan. Patients with IBS or other gastrointestinal disorders may work with their healthcare providers to determine whether ISIga is a suitable treatment option for them.